NO993708L - Opplöselige CTLA 4 mutante molekyler og anvendelse derav - Google Patents

Opplöselige CTLA 4 mutante molekyler og anvendelse derav

Info

Publication number
NO993708L
NO993708L NO993708A NO993708A NO993708L NO 993708 L NO993708 L NO 993708L NO 993708 A NO993708 A NO 993708A NO 993708 A NO993708 A NO 993708A NO 993708 L NO993708 L NO 993708L
Authority
NO
Norway
Prior art keywords
mutant molecules
soluble ctla
ctla
soluble
mutant
Prior art date
Application number
NO993708A
Other languages
English (en)
Other versions
NO993708D0 (no
Inventor
Robert James Peach
Joseph Roy Naemura
Peter S Linsley
Jurgen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO993708D0 publication Critical patent/NO993708D0/no
Publication of NO993708L publication Critical patent/NO993708L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO993708A 1997-01-31 1999-07-30 Opplöselige CTLA 4 mutante molekyler og anvendelse derav NO993708L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3659497P 1997-01-31 1997-01-31
PCT/US1998/001880 WO1998033513A1 (en) 1997-01-31 1998-01-29 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
NO993708D0 NO993708D0 (no) 1999-07-30
NO993708L true NO993708L (no) 1999-09-28

Family

ID=21889481

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993708A NO993708L (no) 1997-01-31 1999-07-30 Opplöselige CTLA 4 mutante molekyler og anvendelse derav

Country Status (17)

Country Link
US (2) US20030035816A1 (no)
EP (2) EP1557173A1 (no)
JP (1) JP2001510473A (no)
KR (1) KR20000070633A (no)
CN (1) CN1244803A (no)
AR (1) AR007225A1 (no)
AU (1) AU725016B2 (no)
BR (1) BR9806764A (no)
CA (1) CA2278771A1 (no)
HU (1) HUP0001971A3 (no)
IL (1) IL130656A0 (no)
NO (1) NO993708L (no)
NZ (1) NZ336009A (no)
PL (1) PL334898A1 (no)
RU (2) RU2235555C2 (no)
WO (1) WO1998033513A1 (no)
ZA (1) ZA98533B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE60127933T2 (de) * 2000-01-03 2008-02-07 Mark L. Merion Station Tykocinski Chimäre proteine und anwendungen
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
KR100889887B1 (ko) * 2000-05-26 2009-03-24 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
CA2411962A1 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TR201807700T4 (tr) * 2000-07-03 2018-06-21 Squibb Bristol Myers Co Çözünür CTLA4 mutant moleküllerinin kullanımları.
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
DE60225914T2 (de) * 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
CN100402660C (zh) * 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
WO2005016266A2 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2612868B1 (en) * 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
MX338825B (es) 2008-10-02 2016-05-03 Emergent Product Dev Seattle Proteinas de enlace a objetivos multiples de antagonistas de cd86.
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TR201807700T4 (tr) * 2000-07-03 2018-06-21 Squibb Bristol Myers Co Çözünür CTLA4 mutant moleküllerinin kullanımları.
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
DE60225914T2 (de) * 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
CN100402660C (zh) * 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
WO2005016266A2 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule

Also Published As

Publication number Publication date
KR20000070633A (ko) 2000-11-25
AU6052598A (en) 1998-08-25
EP0988047A4 (en) 2003-05-14
HUP0001971A2 (hu) 2000-10-28
US20040014171A1 (en) 2004-01-22
EP1557173A1 (en) 2005-07-27
AU725016B2 (en) 2000-10-05
CN1244803A (zh) 2000-02-16
EP0988047A1 (en) 2000-03-29
ZA98533B (en) 1999-07-22
RU2004115039A (ru) 2005-10-27
NO993708D0 (no) 1999-07-30
JP2001510473A (ja) 2001-07-31
BR9806764A (pt) 2000-03-14
PL334898A1 (en) 2000-03-27
US20030035816A1 (en) 2003-02-20
CA2278771A1 (en) 1998-08-06
HUP0001971A3 (en) 2002-01-28
IL130656A0 (en) 2000-06-01
AR007225A1 (es) 1999-10-27
WO1998033513A1 (en) 1998-08-06
RU2235555C2 (ru) 2004-09-10
NZ336009A (en) 2001-06-29

Similar Documents

Publication Publication Date Title
NO993708L (no) Opplöselige CTLA 4 mutante molekyler og anvendelse derav
IS4481A (is) Díhýdrópyramídín og notkun þeirra
NO20000321D0 (no) Farge-reseptive blandinger og belagte produkter
DE69635673D1 (de) Blutsammelsystem und kupplung
DE69516074D1 (de) Steckdoseneinheit und Verlängerungsschnur
NO973180L (no) Sotmaterialer og polymermaterialer hvor slike inngår
PT1019358E (pt) 3,3-diarilpropilaminas sua utilizacao e sua preparacao
FR2758675B1 (fr) Multiplexeur-demultiplexeur en longueurs d'onde
HRP970393A2 (en) N-(4-aryl-thiazol-2-yl)-sulfonamide derivatives and their use
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
NO20004274L (no) Proteaseaktivert reseptor 4 og anvendelse derav
DE69918365D1 (de) Steckverbindungspaar und Steckverbindersatz
NO954944D0 (no) Antikorrosjonspigment og anvendelse derav
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
NO971505D0 (no) Trofinin og trofininhjelperproteiner
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE69510034T2 (de) Trennbare und wiederanschliessbare verbindungsvorrichtung
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
BR9602121A (pt) Poliuretano-poliuréias e sua utilização
NO951448D0 (no) Kontaktering mellom betjenings- og visningsorganer
IL123535A0 (en) Benzoxazindione derivatives and their use
NO983556D0 (no) Formulering og anvendelse
EP1000925A4 (en) TRIPHENYLMETHANE DERIVATIVES AND THEIR USE
FI972010A0 (fi) Arrangemang i en borrningsanordning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application